The novel agent targets CD40 ligand and showed promising results in a two-stage, phase 2 clinical trial, particularly for patients with notable symptom burden but limited systemic organ involvement.
Phase 2 results for dazodalibep in Sjögren’s syndrome to be presented on June 1, 11:35-11:45 a.m. CEST and June 3, 9:35-9:45 a.m. CEST Planned presentations illustrate. | May 23, 2023